In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Promedior Inc.

www.promedior.com

Latest From Promedior Inc.

Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates

Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.

Deals Business Strategies

Roche Paying $390m Up Front For Fibrosis-Fighting Promedior

The deal, which includes up to $1bn for milestones, gives Roche Promedior’s PRM-151, a Phase III-ready asset for IPF that has also completed a Phase II study in myelofibrosis and could be effective in a broad range of fibrotic diseases.

Deals M & A

Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Regulation

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Respiratory Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Ophthalmic
  • Renal System
  • Respiratory, Pulmonary
  • Alias(es)
  • Crovela BioPharm Inc.
  • Medior Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Promedior Inc.
  • Senior Management
  • Jason Lettmann, CEO
    Richard L Jack, PhD, COO & CSO
    Kieran McCarthy, VP, Bus. Dev.
  • Contact Info
  • Promedior Inc.
    Phone: (781) 538-4200
    101 Hartwell Ave.
    Ste. 100
    Lexington, MA 02421
    USA
UsernamePublicRestriction

Register